Compare CLPR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPR | IMMP |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 58.2M |
| IPO Year | 2015 | 2012 |
| Metric | CLPR | IMMP |
|---|---|---|
| Price | $3.50 | $0.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 65.2K | ★ 22.2M |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | ★ 11.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.83 | $0.29 |
| 52 Week High | $4.61 | $3.53 |
| Indicator | CLPR | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 39.53 |
| Support Level | $3.34 | $0.29 |
| Resistance Level | $3.60 | $1.89 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 90.41 | 40.56 |
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.